A new Nordic real‑world study has mapped KRAS and NRAS mutation patterns and outcomes in patients with metastatic colorectal cancer (mCRC) using three complementary cohorts from Finland, Sweden, Norway and Denmark.

Drawing on the prospective Finnish RAXO study, a population‑based cohort from the Uppsala region, and the Scandinavian PRCRC registry, the researchers characterized the frequency and clinical impact of specific RAS mutation subtypes, including KRAS G12C, across routine practice settings.

They report that different RAS mutation groups and selected KRAS variants are associated with distinct survival profiles and treatment trajectories, underscoring the need for granular molecular stratification in mCRC rather than treating all RAS‑mutant disease as a single group.

For drug developers and clinicians, the findings provide Nordic, population‑anchored evidence to inform trial design and optimize the use of current and emerging KRAS‑targeted therapies.

link to article